Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. Chief Operating Officer Travis Whitfill will deliver a virtual presentation on September 8, 2025, at 7:00 AM ET.
The presentation will highlight recent developments, including promising safety results from the Phase 1b trial of ATR-12 for Netherton syndrome and the initiation of patient dosing in the Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated dermal toxicity. Dr. Whitfill will also conduct one-on-one meetings with investors and potential partners during the conference.
Azitra (NYSE American: AZTR), azienda biofarmaceutica in fase clinica specializzata in dermatologia di precisione, parteciperà al 27° H.C. Wainwright Annual Global Investment Conference dall'8 al 10 settembre 2025. Il Chief Operating Officer Travis Whitfill terrà una presentazione virtuale l'8 settembre 2025 alle 7:00 ET.
La presentazione illustrerà gli ultimi sviluppi, tra cui i promettenti risultati di sicurezza dello studio di Fase 1b su ATR-12 per la sindrome di Netherton e l'avvio della somministrazione ai pazienti nello studio di Fase 1/2 su ATR-04 per la tossicità dermica associata agli inibitori EGFR. Il dott. Whitfill incontrerà inoltre investitori e potenziali partner in appuntamenti one-to-one durante la conferenza.
Azitra (NYSE American: AZTR), una compañía biofarmacéutica en etapa clínica especializada en dermatología de precisión, participará en la 27.ª Conferencia Anual Global de Inversión H.C. Wainwright del 8 al 10 de septiembre de 2025. El director de operaciones, Travis Whitfill, ofrecerá una presentación virtual el 8 de septiembre de 2025 a las 7:00 AM ET.
La presentación destacará los desarrollos recientes, entre ellos los prometedores resultados de seguridad del ensayo de Fase 1b de ATR-12 para el síndrome de Netherton y el inicio de la dosificación de pacientes en el ensayo de Fase 1/2 de ATR-04 para la toxicidad dérmica asociada a inhibidores de EGFR. El Dr. Whitfill también mantendrá reuniones individuales con inversores y posibles socios durante la conferencia.
Azitra (NYSE American: AZTR))는 정밀 피부과학을 전문으로 하는 임상 단계의 바이오제약 회사로, 2025년 9월 8일부터 10일까지 열리는 제27회 H.C. Wainwright 연례 글로벌 투자 컨퍼런스에 참여합니다. 최고운영책임자(Chief Operating Officer) 트래비스 휘트필(Travis Whitfill)이 2025년 9월 8일 동부시간(ET) 오전 7시에 가상 발표를 진행합니다.
발표에서는 네스턴턴 증후군에 대한 ATR-12의 1b상에서의 유망한 안전성 결과과 EGFR 억제제 관련 피부독성 치료를 위한 ATR-04의 1/2상에서 환자 투약 개시 등 최근 진행 사항을 중점적으로 소개합니다. 휘트필 박사는 컨퍼런스 기간 동안 투자자와 잠재적 파트너와의 일대일 미팅도 진행할 예정입니다.
Azitra (NYSE American: AZTR), société biopharmaceutique en phase clinique spécialisée en dermatologie de précision, participera à la 27e conférence annuelle mondiale sur l'investissement H.C. Wainwright du 8 au 10 septembre 2025. Le directeur des opérations, Travis Whitfill, donnera une présentation virtuelle le 8 septembre 2025 à 7h00 (ET).
La présentation mettra en lumière les développements récents, notamment les résultats de sécurité prometteurs de l'essai de phase 1b d'ATR-12 pour le syndrome de Netherton et le lancement de l'administration aux patients dans l'essai de phase 1/2 d'ATR-04 pour la toxicité cutanée associée aux inhibiteurs de l'EGFR. Le Dr Whitfill tiendra également des réunions individuelles avec des investisseurs et des partenaires potentiels pendant la conférence.
Azitra (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf präzisionsdermatologie spezialisiert, wird an der 27. H.C. Wainwright Annual Global Investment Conference vom 8. bis 10. September 2025 teilnehmen. Chief Operating Officer Travis Whitfill wird am 8. September 2025 um 7:00 Uhr ET eine virtuelle Präsentation halten.
Die Präsentation wird aktuelle Fortschritte hervorheben, darunter die vielversprechenden Sicherheitsdaten der Phase-1b-Studie zu ATR-12 bei Netherton-Syndrom und den Beginn der Patientenbehandlung in der Phase-1/2-Studie zu ATR-04 bei EGFR-Inhibitor-assoziierter Dermatotoxizität. Dr. Whitfill wird während der Konferenz außerdem Einzelgespräche mit Investoren und potenziellen Partnern führen.
- None.
- None.
In the prerecorded presentation, Mr. Whitfill will highlight recent updates and progress with Azitra's pipeline including the announcement of promising safety results for its Phase 1b clinical trial of the ATR-12 program in Netherton syndrome. The Company also recently announced that the first patient has been dosed in the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated dermal toxicity in adults. The design for the ATR-04 trial was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Details of the presentation are as follows:
Event: | H.C. Wainwright 27th Annual Global Investment Conference |
Date: | September 8-10, 2025 |
Virtual Presentation: | 7:00 AM, ET, September 8, 2025 |
Presenter: | Travis Whitfill Ph.D., MPH, Cofounder and Chief Operating Officer |
Webcast Link: | https://journey.ct.events/view/d825c56c-b598-460e-a0a1-fc989cc43e4f |
During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
About Azitra, Inc.
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to present this abstract detailing the Phase 1/2 clinical trial or, if we are able to do so, that the abstract will be favorably received; we may experience delays in the dosing the first patient in this Phase 1/2 trial; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the SEC on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302545966.html
SOURCE Azitra, Inc.
FAQ
When is Azitra (AZTR) presenting at the H.C. Wainwright Conference 2025?
What clinical trials will Azitra (AZTR) discuss at the H.C. Wainwright Conference?
Who will present for Azitra (AZTR) at the H.C. Wainwright Conference 2025?
How can investors access Azitra's (AZTR) presentation at the H.C. Wainwright Conference?
